Lovinium Cellular Therapy is an innovative new way of thinking about health and aging. Cellular therapy (CT) is the transplantation of human cells to replace or repair damaged tissue and cells. With new technologies, innovative products, and limitless imagination, many different types of cells may be used as a therapy or treatment for various diseases and conditions.
We use regenerative medicine to improve the standard of care for people suffering from conditions where the repair of cells and tissues is required. We perform our cellular therapy treatments by re-activating existing stem cells in the body. We then utilize state-of-the-art technology to deliver these cells to a wound or diseased area.
We know you’re looking for a better way to treat your patients. You want to be able to offer them the most advanced treatments possible, but you also want to make sure that they are safe and effective. You need a solution that can help you do both.
We have the answer: Lovinium-iMSC.
Lovinium-iMSC is an innovative stem cell treatment that uses human induced pluripotent stem cells (iPSC) based on cell reprogramming technology to give your patients the best possible outcomes.
Compared with tissue-derived MSC, iMSC resembles their primary counterparts in morphology, immunophenotype, and three-lineage differentiation capacity while showing more vital regeneration ability in animal disease models. In addition, iPSC can be passed down indefinitely so that the sources of iMSC can be endless and iMSC induced from a single iPSC cell or clone are theoretically more homogeneous.
Human induced pluripotent stem cells (iPSC) are created by reprogramming adult cells into a state that is similar to embryonic stem cells. iPSCs have many advantages over tissue-derived MSC, including the ability to be passed down indefinitely, a closer resemblance to their primary counterparts in morphology and immunophenotype, and stronger regeneration ability in animal disease models.In addition to these advantages, iMSC are derived from individualized sources of stem cells so that they can be used for personalized therapies. They can also be easily expanded in culture and used as models for drug discovery and toxicology testing.
In recent years, the use of umbilical cord mesenchymal stem cells (UC-MSCs) to treat rheumatic immune diseases has garnered increasing attention. The promising results of preclinical studies suggest that UC-MSCs may be a therapeutic method for regenerative medicine.
Umbilical cord mesenchymal stem cells (UC-MSCs) are a class of multifunctional stem cells isolated and cultured from the umbilical cord. They possessed the characteristics of high self-renewal, multi-directional differentiation potential, and low immunogenicity. Its application in tissue engineering and gene therapy has achieved a series of results. MSCs can differentiate into bone and cartilage. Second, these cells inhibit immunity, alleviate inflammation, resist fibrosis, and promote vascular repair.
MSCs have been used to treat some clinically refractory diseases, such as spinal cord injury, cerebral palsy, amyotrophic lateral sclerosis, systemic lupus erythematosus, systemic sclerosis, Crohn’s disease, stroke, diabetes, diabetic foot, and cirrhosis, among other conditions. UC-MSCs have the capacity for tissue repair and regeneration. UC-MSCs secrete a range of growth factors, such as hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), stromal cell-derived factor-1 (SDF-1), keratinocyte growth factor (KGF), fibroblast growth factor (FGF), and insulin-like growth factor-1 (IGF-1), to facilitate proliferation and tissue damage repair.